Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region and Competition, 2020-2030F
류마티스 치료제 세계 시장 규모는 2024년 261억 1,000만 달러에서 2030년에는 370억 5,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 5.98%로 성장할 것으로 예상됩니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
261억 1,000만 달러 |
| 시장 규모 : 2030년 |
370억 5,000만 달러 |
| CAGR : 2025-2030년 |
5.98% |
| 급성장 부문 |
온라인 약국 |
| 최대 시장 |
북미 |
류마티스 치료제는 주로 근골격계(관절, 근육, 뼈, 결합조직)에 영향을 미치는 류마티스 질환의 진단과 치료에 초점을 맞춘 의학의 전문 분야입니다. 이러한 질환은 일반적으로 관절의 통증, 뻣뻣함, 염증, 움직임의 제한으로 나타납니다. 치료적 접근은 증상을 완화하고, 질병의 진행을 관리하며, 환자의 삶의 질을 향상시키는 것을 목표로 합니다.
류마티스 관절염, 골관절염, 루푸스 등 류마티스 질환의 발생률과 유병률 증가는 류마티스 치료제 수요를 촉진하고 있습니다. TNF 억제제, 인터루킨 억제제, JAK 억제제 등 생물학적 제제는 보다 효과적인 치료 옵션을 도입하기 위한 지속적인 연구 개발로 인해 지속적으로 시장을 주도하고 있습니다.
주요 시장 성장 촉진요인
류마티스 질환의 유병률 상승
주요 시장 이슈
치료비 폭등
바이오시밀러는 치료비를 절감할 수 있는 잠재력을 가지고 있지만, 의료진과 환자들 시장 거부감과 제한된 인식으로 인해 광범위한 채택에 걸림돌로 작용하고 있습니다.
주요 시장 동향
환자 중심 치료로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 적응증별(강직성 척추염, 통풍, 골관절염, 건선성 관절염, 류마티스 관절염)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 북미의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제9장 남미의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 류마티스 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 류마티스 치료제 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- Amgen Inc.
- Novartis AG
- Janssen Pharmaceuticals, Inc.
- Sanofi SA
- Johnson & Johnson Private Limited
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
Global Rheumatology therapeutics market was valued at USD 26.11 billion in 2024 and is projected to reach USD 37.05 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.98% during the forecast period.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 26.11 Billion |
| Market Size 2030 | USD 37.05 Billion |
| CAGR 2025-2030 | 5.98% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Rheumatology therapeutics is a specialized area of medical science focused on the diagnosis and treatment of rheumatic diseases, which primarily affect the musculoskeletal system-joints, muscles, bones, and connective tissues. These conditions commonly manifest as joint pain, stiffness, inflammation, and limited mobility. The therapeutic approach aims to alleviate symptoms, manage disease progression, and enhance the quality of life for patients.
The increasing incidence and prevalence of conditions such as rheumatoid arthritis, osteoarthritis, and lupus are fueling demand for rheumatology therapeutics. Key contributing factors include an aging global population and lifestyle-related changes. Biologic therapies-such as TNF inhibitors, interleukin inhibitors, and JAK inhibitors-continue to dominate the market, driven by ongoing R&D introducing more effective treatment options.
Key Market Drivers
Rising Prevalence of Rheumatic Diseases
The growing global burden of rheumatic conditions-including osteoarthritis, rheumatoid arthritis, and gout-can be attributed to several interrelated factors. Aging demographics are a major contributor, with conditions like osteoarthritis increasing proportionally with age. In 2019, approximately 528 million people globally were affected by osteoarthritis, representing a 113% rise since 1990. Nearly 73% of these individuals were over the age of 55.
Obesity is another key risk factor. In 2022, one in eight people globally were classified as obese, with adult obesity rates more than doubling since 1990. Additionally, sedentary lifestyles-prevalent in modern societies-have been linked to a surge in musculoskeletal and joint disorders. As of 2022, nearly one-third of adults worldwide were insufficiently physically active.
Genetic predisposition also plays a significant role. For example, heritability in rheumatoid arthritis is estimated at around 60%, with strong associations to specific genetic markers such as HLA. Environmental factors like air pollution have also been linked to the development and exacerbation of these conditions.
Improvements in diagnostic tools and heightened awareness among healthcare professionals have led to earlier and more accurate diagnoses. In the U.S., 21.2% of adults-approximately 53.2 million people-were diagnosed with arthritis between 2019 and 2021. Many of these diseases are chronic, further increasing prevalence due to long-term disease management.
Gender disparities are also notable; rheumatoid arthritis affects women two to three times more frequently than men. Additionally, rheumatic conditions often coexist with comorbidities such as cardiovascular disease and diabetes, compounding the healthcare burden. Regional differences in diet, healthcare access, and lifestyle also influence prevalence rates. Collectively, these factors underscore the growing need for effective rheumatology therapeutics and continued innovation in treatment approaches.
Key Market Challenges
High Cost of Treatment
One of the primary challenges in the rheumatology therapeutics market is the high cost of treatment, particularly for biologic drugs. Despite insurance coverage, patients frequently incur substantial out-of-pocket expenses, leading to treatment non-adherence and poorer health outcomes.
These high costs can exacerbate disparities in care access, particularly among lower-income populations, resulting in delayed diagnoses and suboptimal treatment. Publicly funded healthcare systems also face budgetary constraints that limit the availability and quality of rheumatologic treatments.
Moreover, the cost burden extends to health insurers and employers, often resulting in increased insurance premiums. Concerns over affordability have prompted discussions among policymakers and advocacy groups regarding drug pricing reforms and greater transparency in healthcare costs.
Rheumatic diseases can significantly impair physical functioning, resulting in decreased work productivity and higher disability rates. The combined effect of disease burden and high treatment costs poses economic challenges for individuals and healthcare systems alike.
Although biosimilars hold promise for reducing treatment costs, broader adoption remains a hurdle due to market hesitancy and limited awareness among healthcare providers and patients.
Key Market Trends
Shift Toward Patient-Centric Care
The market is witnessing a paradigm shift toward patient-centered care, with a strong emphasis on shared decision-making. Healthcare providers are involving patients in the development of personalized treatment plans, taking into account disease severity, lifestyle, comorbidities, and individual preferences.
Education and empowerment are integral components of this approach. By equipping patients with a better understanding of their condition and available treatment options, providers can foster more active patient participation in disease management.
Efforts are also being made to address access and affordability challenges. Healthcare institutions are working to minimize financial barriers and ensure equitable access to necessary treatments.
Patient-centric models promote continuous monitoring of disease activity, encouraging patients to communicate regularly with their healthcare teams. Pain management, as a core concern, is customized based on individual needs.
Key Market Players
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- Amgen Inc.
- Novartis AG
- Janssen Pharmaceuticals, Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche Ltd
Report Scope:
In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Rheumatology Therapeutics Market, By Indication:
- Ankylosing Spondylitis
- Gout
- Osteoarthritis
- Psoriatic Arthritis
- Rheumatoid Arthritis
Rheumatology Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Rheumatology Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.
Available Customizations:
Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Rheumatology Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Rheumatology Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Indication
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Rheumatology Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Indication
- 6.3.1.2.2. By Distribution Channel
- 6.3.2. India Rheumatology Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Indication
- 6.3.2.2.2. By Distribution Channel
- 6.3.3. Australia Rheumatology Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Indication
- 6.3.3.2.2. By Distribution Channel
- 6.3.4. Japan Rheumatology Therapeutics Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Indication
- 6.3.4.2.2. By Distribution Channel
- 6.3.5. South Korea Rheumatology Therapeutics Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Indication
- 6.3.5.2.2. By Distribution Channel
7. Europe Rheumatology Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Rheumatology Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Indication
- 7.3.1.2.2. By Distribution Channel
- 7.3.2. Germany Rheumatology Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Indication
- 7.3.2.2.2. By Distribution Channel
- 7.3.3. Spain Rheumatology Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Indication
- 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Rheumatology Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Indication
- 7.3.4.2.2. By Distribution Channel
- 7.3.5. United Kingdom Rheumatology Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Indication
- 7.3.5.2.2. By Distribution Channel
8. North America Rheumatology Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Rheumatology Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Indication
- 8.3.1.2.2. By Distribution Channel
- 8.3.2. Mexico Rheumatology Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Indication
- 8.3.2.2.2. By Distribution Channel
- 8.3.3. Canada Rheumatology Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Indication
- 8.3.3.2.2. By Distribution Channel
9. South America Rheumatology Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Rheumatology Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Indication
- 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Rheumatology Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Indication
- 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Rheumatology Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Indication
- 9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Rheumatology Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Rheumatology Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Indication
- 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Rheumatology Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Indication
- 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Rheumatology Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Indication
- 10.3.3.2.2. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Rheumatology Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. AbbVie Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Bristol-Myers Squibb Company
- 16.3. Pfizer Inc.
- 16.4. Merck & Co., Inc.
- 16.5. Amgen Inc.
- 16.6. Novartis AG
- 16.7. Janssen Pharmaceuticals, Inc.
- 16.8. Sanofi SA
- 16.9. Johnson & Johnson Private Limited
- 16.10. Takeda Pharmaceutical Company Limited
- 16.11. F. Hoffmann-La Roche Ltd
17. Strategic Recommendations
18. About Us & Disclaimer
